Research Study

A Phase 2, Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of the Oral GnRH Antagonist TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate Cancer
Principal Investigator 
Kim Nguyen Chi

Overview

Body Locations and Systems 
Prostate Cancer
Disorders and Conditions 
Cancers
ClinicalTrials.gov# 
NCT02083185
Status 
Closed to Recruitment
Study Start/End 
Jul 25, 2014 to Mar 1, 2016
Locations 
Vancouver General Hospital
Name/Title 
Shane Brown, Study Coordinator
Phone 
604-877-6000 ext.2370
Email Address 
sbrown9@bccancer.bc.ca
Purpose of Study 

This is a 3-arm, randomized, open-label, parallel group study of TAK-385, together with a leuprorelin observational cohort, in patients with prostate cancer who require first-line androgen deprivation therapy (ADT).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.